argenx SE (Nasdaq: ARGX) provided an update to its Phase 1/2 clinical trial of ARGX-110 in cutaneous T-cell lymphoma and announced a proposed public offering of $150 million American Depositary Shares. Shares of the biopharmaceutical leaped $24.02 to close at $54.47.